Analysis of microRNA levels in cerebrospinal fluid of patients with primary brain tumors and metastases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00071459" target="_blank" >RIV/65269705:_____/19:00071459 - isvavai.cz</a>

Výsledek na webu

<a href="https://wfns2019.medmeeting.org/Home/AbstractSearchEn/8292" target="_blank" >https://wfns2019.medmeeting.org/Home/AbstractSearchEn/8292</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Analysis of microRNA levels in cerebrospinal fluid of patients with primary brain tumors and metastases

Popis výsledku v původním jazyce

Primary brain tumors and brain metastases counts yearly around 40 patients per 100 000 persons in the world and their incidence rate is still growing. Prognosis and therapy differ between brain tumor types and, therefore, accurate and early diagnosis might improve survival and life quality of patients. Cerebrospinal fluid (CSF) has many important functions and baths extracellular environment of the central nervous system, and thus is supposed to reflect all pathological conditions. From this perspective, CSF looks as ideal source of diagnostic biomarkers. MikroRNAs (miRNAs), short non-coding RNAs involved in the pathogenesis of many cancers including brain tumors, might represent group of new biomarkers. In addition, dysregulated levels of brain tumor specific miRNAs have been already observed also in CSF. Following these facts, analysis of CSF miRNAs in brain tumor patients might help to develop new diagnostic platform enabling more precise diagnosis. We have observed that CSFs from patients with various primary brain tumors and metastases are characterized by specific miRNA signatures.

Název v anglickém jazyce

Analysis of microRNA levels in cerebrospinal fluid of patients with primary brain tumors and metastases

Popis výsledku anglicky

Primary brain tumors and brain metastases counts yearly around 40 patients per 100 000 persons in the world and their incidence rate is still growing. Prognosis and therapy differ between brain tumor types and, therefore, accurate and early diagnosis might improve survival and life quality of patients. Cerebrospinal fluid (CSF) has many important functions and baths extracellular environment of the central nervous system, and thus is supposed to reflect all pathological conditions. From this perspective, CSF looks as ideal source of diagnostic biomarkers. MikroRNAs (miRNAs), short non-coding RNAs involved in the pathogenesis of many cancers including brain tumors, might represent group of new biomarkers. In addition, dysregulated levels of brain tumor specific miRNAs have been already observed also in CSF. Following these facts, analysis of CSF miRNAs in brain tumor patients might help to develop new diagnostic platform enabling more precise diagnosis. We have observed that CSFs from patients with various primary brain tumors and metastases are characterized by specific miRNA signatures.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/NV18-03-00398" target="_blank" >NV18-03-00398: Rozšíření současných prognostických skórovacích systémů u mozkových metastáz o mikroRNA profilování s cílem individualizace pooperační péče</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů